<div id="readability-page-1"><div>By Katherine Hamilton Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone. Sogroya is now indicated for kids aged 2.5 years and older with disorders affecting their height, including idiopathic short stature, short stature born small for gestational age, or growth failure associated with Noonan Syndrome. It is also indicated for children of the same age group and adults with growth hormone deficiency. Sogroya is a once-weekly injection which comes in 5 mg, 10 mg and 15 mg dosages. Novo Nordisk has been studying Sogroya as a way for people with growth disorders to avoid daily injections. In a study, Sogroya demonstrated non-inferiority compared with daily somatropin and growth hormone dosages. Novo Nordisk also submitted a supplemental application for Sogroya's approval in the U.S. for Turner Syndrome. A decision is expected later this year, the company said. Write to Katherine Hamilton at katherine.hamilton@wsj.com (END) Dow Jones Newswires02-27-26 1633ET</div></div>

诺和诺德公司

诺和诺德公司已获得 FDA 批准，将 Sogroya（生长激素治疗）用于 2.5 岁及以上儿童的身高相关疾病的新适应症，包括特发性矮小和生长激素缺乏症。Sogroya 是一种每周注射一次的药物，提供 5 毫克、10 毫克和 15 毫克的剂量，旨在减少每日注射的需求。该公司还在等待对今年晚些时候申请的特纳综合症补充申请的决定

FDA 批准诺和诺德公司的生长障碍治疗药物用于新的患者群体